| Nov 8 |
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 6 |
Tango stock plunges 28% amid pipeline updates, Q3 earnings report
|
| Nov 6 |
Tango Therapeutics GAAP EPS of -$0.27 beats by $0.07, revenue of $11.6M beats by $3.53M
|
| Nov 6 |
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
|
| Nov 6 |
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
|
| Oct 29 |
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
|
| Sep 10 |
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
|
| Aug 18 |
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
|
| Aug 9 |
Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 7 |
Tango Therapeutics GAAP EPS of -$0.24, revenue of $19.87M
|
